scholarly journals Clinical characteristics and management of hospitalized and ambulatory patients with heart failure–results from ESC heart failure long‐term registry–Egyptian cohort

2015 ◽  
Vol 2 (3) ◽  
pp. 159-167 ◽  
Author(s):  
Mahmoud Hassanein ◽  
Magdy Abdelhamid ◽  
Bassem Ibrahim ◽  
Ahmed Elshazly ◽  
Mohamed Wafaie Aboleineen ◽  
...  
Cor et Vasa ◽  
2015 ◽  
Vol 57 (1) ◽  
pp. e6-e11 ◽  
Author(s):  
Jan Krupička ◽  
Anna Andrusková ◽  
Markéta Hegarová ◽  
Marie Lazarová ◽  
Filip Málek ◽  
...  

2005 ◽  
Vol 58 (7) ◽  
pp. 789-796
Author(s):  
Stella Maris Macín ◽  
Eduardo Roque Perna ◽  
Natalia Augier ◽  
Jorge Cialzeta ◽  
Eduardo Francisco Farías ◽  
...  

2011 ◽  
Vol 150 (3) ◽  
pp. 338-339 ◽  
Author(s):  
Miyuki Tsuchihashi-Makaya ◽  
Sanae Hamaguchi ◽  
Shintaro Kinugawa ◽  
Kazutomo Goto ◽  
Daisuke Goto ◽  
...  

Heart ◽  
2018 ◽  
Vol 105 (1) ◽  
pp. 34-41 ◽  
Author(s):  
Wilson Nadruz ◽  
Erin West ◽  
Morten Sengeløv ◽  
Gabriela L Grove ◽  
Mário Santos ◽  
...  

ObjectiveThis study compared the clinical features, cardiac structure and function evaluated by echocardiography, cardiopulmonary response to exercise and long-term clinical outcomes between patients with heart failure (HF) induced by cancer therapy (CTHF) and heart failure not induced by cancer therapy (NCTHF).MethodsWe evaluated 75 patients with CTHF and 894 with NCTHF who underwent clinically indicated cardiopulmonary exercise testing, and followed these individuals for a median of 4.5 (3.0–5.8) years, during which 187 deaths and 256 composite events (death, heart transplantation and left ventricular (LV) assistant device implantation) occurred.ResultsCompared with NCTHF, patients with CTHF were younger, with lower prevalence of cardiovascular comorbidities, higher LV ejection fraction (LVEF), but similar global longitudinal strain. LV diastolic function (higher E/e′ ratio) and compliance (higher end-diastolic pressure/LV end-diastolic volume index ratio) were worse in CTHF and were both associated with adverse outcomes. Despite a favourable clinical profile, peak VO2 and VE/VCO2 slope were similarly impaired in CTHF and NCTHF. In multivariable Cox regression analysis including clinical characteristics, cardiopulmonary exercise testing variables and LVEF, CTHF was associated with a significantly higher risk of death (HR 2.64; 95% CI 1.53 to 4.55; p=0.001) and composite events (HR 1.79; 95% CI 1.10 to 2.91; p=0.019) compared with NCTHF.ConclusionsCTHF is characterised by a distinct clinical profile, better LVEF but worse LV diastolic properties, and similarly impaired global longitudinal strain, functional capacity and ventilatory efficiency. Accounting for differences in clinical characteristics, CTHF was associated with worse long-term prognosis than NCTHF.


2000 ◽  
Vol 86 (8) ◽  
pp. 863-867 ◽  
Author(s):  
Christopher M O’Connor ◽  
Wendy A Gattis ◽  
Linda Shaw ◽  
Michael S Cuffe ◽  
Robert M Califf

Open Heart ◽  
2021 ◽  
Vol 8 (2) ◽  
pp. e001704
Author(s):  
Andrew Abboud ◽  
Austin Nguonly ◽  
Asher Bean ◽  
Kemar J Brown ◽  
Roy F Chen ◽  
...  

IntroductionPatients with heart failure (HF) are classically categorised by left ventricular ejection fraction (LVEF). Efforts to predict outcomes and response to specific therapy among LVEF-based groups may be suboptimal, in part due to the underlying heterogeneity within clinical HF phenotypes. A multidimensional characterisation of ambulatory patients with and without HF across LVEF groups is needed to better understand and manage patients with HF in a more precise manner.Methods and analysisTo date, the first cohort of 1313 out of total planned 3000 patients with and without HF has been enroled in this single-centre, longitudinal observational cohort study. Baseline and 1-year follow-up blood samples and clinical characteristics, the presence and duration of comorbidities, serial laboratory, echocardiographic data and images and therapy information will be obtained. HF diagnosis, aetiology of disease, symptom onset and clinical outcomes at 1 and 5 years will be adjudicated by a team of clinicians. Clinical outcomes of interest include all-cause mortality, cardiovascular mortality, all-cause hospitalisation, cardiovascular hospitalisation, HF hospitalisation, right-sided HF and acute kidney injury. Results from the Preserved versus Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Patients with Heart Failure (PREFER-HF) trial will examine longitudinal clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand HF phenotypes, with the ultimate goal of improving precision medicine and clinical outcomes for patients with HF.Ethics and disseminationInformation gathered in this research will be published in peer-reviewed journals. Written informed consent for PREFER-HF was obtained from all participants. All study procedures were approved by the Mass General Brigham Institutional Review Board in Boston, Massachusetts and performed in accordance with the Declaration of Helsinki (Protocol Number: 2016P000339).Trial registration numberPREFER-HF ClinicalTrials.gov identifier: NCT03480633.


Sign in / Sign up

Export Citation Format

Share Document